Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 40245, held by Chartwell Rx. Carisoprodol.
As of Nov 16, 2026, ANDA 40245 (Carisoprodol), held by Chartwell Rx, was first approved by FDA on Sep 8, 1997, with 4 approved supplements and 0 published complete response letters.
Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol Tablets, USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 8, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Jul 26, 2013 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 24, 2011 | Supplement 7Labeling | Approved | None posted |
| Jan 29, 2009 | Supplement 5Labeling | Approved | None posted |
| Nov 29, 2006 | Supplement 3Labeling | Approved | None posted |
| Sep 8, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters